Semaglutide Compare Semaglutide Compare
Comparison basics

This week’s comparison update: where the parent site now sends Wegovy, Mounjaro and tablet questions

An update on how the parent site now routes broader questions into the right specialist comparison without losing the educational overview.

20 May 2026 2 min read Information only
Before comparing providers This article gives general UK comparison context. Suitability for treatment depends on assessment by a regulated healthcare professional.

One of the most important questions on a parent comparison site is simple: when should you stay on the broad comparison hub, and when should you switch into a more specialist page? This week’s update is about making that handoff clearer for Wegovy, Mounjaro and tablet questions.

What stays on the parent site

The parent site is designed for broad comparison questions. That includes treatment routes, provider types, NHS vs private access, cost context, tablet comparison, and the first stage of provider checks.

That means the parent site is usually the best place to start if the question is still wide, such as:

  • Should I be comparing injections or tablets?
  • How do pharmacy-led and programme-led services differ?
  • What should I look for beyond the headline price?
  • Which provider questions matter before I go deeper?

When the specialist sites become more useful

Once the reader’s question becomes specifically about Wegovy or Mounjaro provider detail, dose-stage context or current medicine-specific price rows, the narrower specialist site is usually the better next step.

  • Wego Compare is the better fit when the question is specifically about Wegovy provider detail and dose context.
  • Jaro Compare is the better fit when the question is specifically about Mounjaro provider detail and dose context.
  • The parent tablet comparison page remains the main comparison guide for current tablets and capsules.
  • GLP1 Tablets is more useful for future oral GLP-1 background rather than today’s pack-based tablet comparison.

Why this matters

A broad site can become confusing if it tries to be both the parent comparison hub and the deepest medicine-specific destination at the same time. The clearer split makes it easier for readers to start broad and then move into the right narrower comparison only when they actually need it.

Related reading

More semaglutide reading

How private semaglutide providers describe assessment, delivery and follow-up Headline price rarely tells the whole story. Private semaglutide provider pages also differ on assessment, delivery, support and repeat review. Semaglutide brand confusion in the UK: why Ozempic, Wegovy and Rybelsus get mixed up Semaglutide search intent often starts with a brand name, but UK routes diverge quickly once Wegovy, Ozempic and Rybelsus are separated properly. Generic semaglutide in Canada: what it does and does not mean for the UK Canada has approved generic semaglutide injections, but that does not mean a generic Wegovy route or new UK provider access is here. This is what the change actually means.
Last reviewed: 2026-05-24 Checked against: current public provider and brand pages

Important information

This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.

Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, source checks or editorial context are presented.

Source check: Brand role, provider wording, public pricing and availability can change. Confirm current details directly with the provider before taking the next step.